The role of TRPV6 in breast carcinogenesis

Katrin A. Bolanz, Matthias A. Hediger, and Christopher P. Landowski

Institute of Biochemistry and Molecular Medicine, University of Bern, Switzerland

Abstract

TRPV6 is an endothelial calcium entry channel that is strongly expressed in breast adenocarcinoma tissue. In this study, we further confirmed this observation by analysis of breast cancer tissues, which indicated that TRPV6 mRNA expression was up-regulated between 2-fold and 15-fold compared with the average in normal breast tissue. Whereas TRPV6 is expressed in the cancer tissue, its role as a calcium channel in breast carcinogenesis is poorly understood. Therefore, we investigated how TRPV6 affects the viability, apoptosis, and calcium transport in the breast cancer cell line T47D. Hormones can also affect the tumor development; hence, we determined the effects of estradiol, progesterone, and 1,25-vitamin D on TRPV6 transcription. Interestingly, the estrogen receptor antagonist tamoxifen reduced expression of TRPV6 and is able to inhibit its calcium transport activity (IC50, 7.5 μmol/L). The in vitro model showed that TRPV6 can be regulated by estrogen, progesterone, tamoxifen, and 1,25-vitamin D and has a large influence on breast cancer cell proliferation. Moreover, the effect of tamoxifen on cell viability was enhanced when TRPV6 expression was silenced with small interfering RNA. TRPV6 may be a novel target for the development of calcium channel inhibitors to treat breast adenocarcinoma expressing TRPV6. [Mol Cancer Ther 2008;7(2):271–279]

Introduction

Ionized calcium (Ca2+) is a central signaling ion that is critical for controlling growth, proliferation, and survival of normal and malignant cells. In cellular processes, calcium is a key modulator of numerous enzymes located in the cytosol, organelles, and nucleus. Ca2+ cannot be degraded like other second messenger signals. Therefore, the intracellular free calcium levels are tightly regulated on multiple levels by plasma membrane ion channels, ion exchangers, pumps, and Ca2+ binding proteins, as well as by the release of calcium from the endoplasmic reticulum and nuclear envelope (1, 2).

One such plasma membrane channel is the TRPV6 calcium entry channel. TRPV6 is a Ca2+ permeable ion channel that was identified using expression cloning by Hediger and colleagues in 1999 (3). TRPV6 plays a central role in total body calcium homeostasis, and its regulation directly affects intestinal calcium absorption, renal calcium excretion, and bone metabolism (4). TRPV6 seems to play a major role in facilitating the entry of Ca2+ into absorptive epithelial cells. This is evident in TRPV6 knockout mice, which exhibit defective intestinal Ca2+ absorption, increased urinary Ca2+ excretion, and decreased bone mineral density. Regulation of TRPV6 is controlled by 1,25-vitamin D, estrogen, and dihydrotestosterone (5–7).

Whereas TRPV6 functions to maintain normal calcium homeostasis, it also seems to play a role in tumor development and progression. TRPV6 was observed to be up-regulated in tissue samples originating from prostate, breast, thyroid, colon, ovary, and pancreatic tumors (8). The channel has been localized to the apical membrane where it delivers calcium into the cells. Furthermore, it has been shown that TRPV6 is most strongly expressed in advanced stages of prostate cancer, whereas there is little to no expression evident in healthy tissue and benign prostate hyperplasia (7, 9). The transcript levels in both studies correlated positively with tumor progression and aggressiveness as indicated by the pathologic stage and Gleason scores of the prostate tumors. Endogenous store-operated channels play important roles in the apoptosis of LNCaP prostate cancer cells (10, 11). Numerous studies have linked enhanced endoplasmic reticulum Ca2+ accumulation to proliferation and/or apoptosis in prostate cancer (12–14). A study by Schwarz et al. (2006) showed that TRPV6 clearly increases the rate of Ca2+-dependent cell proliferation in HEK cells (15).

In mammary adenocarcinoma tissue, immunohistologic analysis showed a clear enhancement in TRPV6 expression over normal tissue, suggesting that it may play some role in the tumor development (8). Data from epidemiologic studies suggest that higher intake of dietary calcium, which lowers 1,25-vitamin D levels in the blood, reduces the breast cancer risk in premenopausal women (16, 17). Calcium also seems important to breast cancer progression because bone metastases occur in up to 70% of patients with advanced breast cancer (18). The metastatic cells at the bone are thus exposed to increased levels of free extracellular Ca2+ released from the mineralized bone matrix.

The most common hormonal treatment for hormone receptor–positive breast adenocarcinoma is the selective...
TRPV6 in Breast Cancer

The cells were split twice a week.

**Materials and Methods**

**Materials**

T47D cells were obtained from NIH Culture Collection. Plastic six-well culture dishes, 96-well culture dishes, and T75 cultivation flasks were obtained from BD Falcon. RPMI 1640 cell culture medium, fetal bovine serum, trypsin, and penicillin/streptomycin were from Life Technologies. Trizol reagent for RNA isolation was purchased from Invitrogen. TaqMan Universal Master Mix for real-time PCR was from Applied Biosystems. Small interfering RNAs (siRNA) and HiPerFect transfection reagent were obtained from Qiagen.

**Rapid-Scan Gene cDNA Panel** was purchased from Origene. h-estradiol, and 25-Dihydroxyvitamin D3, estrogen receptor modulator tamoxifen. It blocks estrogens from signaling through the estrogen receptor and reduces the growth signals to the cells. The activity of tamoxifen can be observed best in breast tumors that express estrogen receptor and/or progesterone receptor. The highest response rates are observed in tumors expressing both estrogen receptor and progesterone receptor (70%), with lower response rates in estrogen receptor-negative/progesterone receptor-positive tumors (45%) and estrogen receptor-positive/progesterone receptor-negative tumors (34%; refs. 19, 20). The lowest tamoxifen response rates are found in estrogen receptor-negative/progesterone receptor-negative tumors (<10%). However, a portion of the supposed nonresponders may actually be attributable to false-negative assay data (21, 22).

Little is known about the calcium entry mechanisms by which intracellular calcium is regulated in breast cancer cells. Therefore, in this study, we investigated how TRPV6 affects proliferation, apoptosis, and calcium transport in the breast cancer cell line T47D. Additionally, the hormonal effects of estradiol, progesterone, and 1,25-vitamin D on TRPV6 expression were determined in the breast cancer cells. The apparent importance of calcium to breast tumor survival may lead to a therapeutic approach particularly apt for the treatment of breast tumors that are independent of estrogen and progesterone. These late stage tumors are highly metastatic and lethal, and there is currently no effective treatment strategy. Understanding the relationship between calcium uptake induced through TRPV6 and the progression of breast tumor types might unveil TRPV6 as a novel target for anticancer drug development.

**siRNA Treatment**

For TRPV6 knockdown, the following siRNAs were used:

- siRNA1 (target sequence): CTG CAT GTC AGA GCA CTT TAA
- siRNA2 (target sequence): AAC CTG CGA CAG CAG AAG AGG
- siRNA control: AAT CAT CTA AGC TGG CCT TGC.

The cells were seeded in 2 mL of culture medium at 400,000 cells per well in six-well plates. After 24 h, siRNA was diluted in phenol red-free medium without fetal bovine serum to give a final siRNA concentration of 5 nmol/L (20 μmol/L stock). Then, HiPerFect was added according to the manufacturer’s protocol, and the mixture was incubated for 10 min at room temperature and added drop-wise onto cells. Cells were incubated with siRNAs for 72 h before isolating RNA using the Trizol RNA isolation method according to manufacturer’s protocol.

**Hormonal Treatments**

For hormone treatment, T47D cells were seeded at 400,000 cells per well in six-well dishes and grown for 48 h. Cells were serum-starved for 24 h before treatment. Then, cells were treated in the above-mentioned culture medium without fetal bovine serum for the duration of the studies. After pilot studies to determine appropriate concentrations, 100 nmol/L 1,25-dihydroxyvitamin D (100 μmol/L stock), 10 nmol/L estradiol (10 μmol/L stock), 100 nmol/L progesterone (100 μmol/L stock), and 1 μmol/L tamoxifen (1 mmol/L stock) were all dissolved in ethanol and applied to the cells along with ethanol-only controls for 24 to 72 h. Dose-response studies during a 24-h treatment time were done with estradiol and 1,25-dihydroxyvitamin D.

Total RNA was harvested after 24, 48, and 72 h of treatment. Three independent experiments were done with every treatment in triplicate. TRPV6 mRNA expression was determined by real-time PCR.

**Real-time PCR**

cDNA was prepared for every sample by reverse transcription of total RNA using TaqMan Reverse Transcription Reagents (Applied Biosystems) according to the manufacturer’s manual. For all experiments, mRNA expression was measured by real-time PCR using an Applied Biosystems 7500 Real-Time PCR System. Reactions consisted of 1× Mastermix, 0.9 μmol/L forward and reverse primers, and 0.2 μmol/L dual-labeled fluorescent probes each for TRPV6 and β-actin. The sequences of the forward and reverse primers for TRPV6 were 5-GGT TCC TGC GGG TGG AA-3 and 5-CTT GTG CCT AGC GTT GGA T-3 respectively, with the resulting amplicon being 62 bp with a Tm of 60°C. The sequence of the probe for TRPV6 was 5-ACA GCC AAG ATC TCA ACC GGC ACC-3. The sequences of the forward and reverse primers for β-actin were 5-CTT GGC ACC CAG CAC AAT-3 and 5-GCC GAT CCA CAC GGA ATA CT-3, respectively, with the resulting amplicon being 69 bp with a Tm of 60°C. The sequence of the probe for β-actin was 5-ATC AAG ATC ATT CCT CCT CAG CGC-3. The specificity of all primers was...
confirmed by BLAST search. Primer Express (Applied Biosystems) was used for designing primers for TRPV6 and β-actin. All primers were designed to cross exon-exon boundaries of the coding sequence. Primers were optimized and validated for the comparative Ct method, as described in the manufacturer's manual. ABI Prism SDS software version 1 was used for the analysis of the amplification plots. The TRPV6 expression values were normalized to β-actin and then compared. The results are shown as fold change ± SD.

Cell Viability and Apoptosis
Cell viability experiments were carried out in 96-well culture plates with an initial cell number of 2,500 cells per well to determine the influence of different hormones on cell growth. To determine the effect of siRNA on cell viability, the cells were seeded at 5,000 cells per well. After the cells were plated for 24 h, siRNA treatment was done for 72 h with 5 nmol/L siRNA. Before absorbance measurements, plates were kept continuously in cling film during incubation and the wells on the outer edge were not used for measurements. After incubation time, the number of living cells was determined by the Cell Proliferation Kit II (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt; Roche) following the manufacturer's instructions. Briefly, 50 μL of 2,3-bis[2-methoxy-4-nitro-5-sulphenyl]-2H-tetrazolium-5-carboxanilide inner salt labeling mixture (including electron-coupling reagent N-methyl dibenzopyrazine methyl sulfate) were added to each well, and plates were incubated for 4 h. The absorbance was measured by an ELISA reader (V<sub>max</sub>, microplate reader; Molecular Devices) at 450 nm with a reference wavelength of 650 nm.

Apo-one homogenous caspase-3/caspase-7 assay (Promega) was done according to manufacturer’s protocol. Cells and siRNAs were prepared as described above with the viability assay. The profluorescent substrate was added to the cells for 3 h before measuring the caspase activity on the Flexstation II (485 nm excitation and 527 nm emission). The percentage of apoptotic cells was calculated relative to the untreated control cells.

Ca<sup>2+</sup> Uptake Activity Measurement
Five thousand cells per well were seeded in a black 96-well plate with 50 μL culture medium per well. After cells have been plated for 24 h, siRNA treatment was done with 5 nmol/L siRNA as described previously. Subsequently, after 72 h, the calcium uptake activity was observed in real time using the FLIPR calcium 3 assay kit (Molecular Devices) according to the manufacturer’s manual. Briefly, 50 μL of calcium-free loading buffer were added to the cell medium. Then 100 μL of calcium 3 dye were added and incubated with the cells for 1 h at 37°C. The plate was put into the Flexstation II, EGTA (final, 5 mmol/L) was added to the cells to deplete intracellular calcium stores, and finally, calcium solution (10 mmol/L final) was added to the cells to observe calcium entry. Fluorescence units per second was calculated from the slope of the uptake curve to show the calcium uptake activity after siRNA treatment. Calcium uptake activity mediated by TRPV6 was also done in Xenopus oocytes using 45Ca<sup>2+</sup>, as done previously (3).

Reverse Transcription – PCR
The Promega Access Reverse Transcription–PCR System was used according to the manufacturer’s instructions for detection of calcium channel expression in T47D cells. After an initial heating step at 45°C for 45 min, the reactions were heated for 2 min at 94°C as a denaturing step. Subsequently, the cycle included a 30-s denaturing step, annealing at 60°C for 15 s, and extension reaction for 30 s at 68°C. Twenty-four cycles resulted in optimal linear amplification of products. A final extension was done for 5 min at 68°C. Samples were stored at −20°C before electrophoresis on a 1% agarose gel.

The following primers were used:

- TRPC1A: forward 5-TCTGCCCCAAAGGCCATGTG-3
  reverse 5-GGGTATACTACTCTCTCCATAATTC-3
- TRPC2: forward 5-CGGCCGCCAGCAGTAGATTG-3
  reverse 5-CCAGCCCCCTTGTGATTTA-3
- TRPC3: forward 5-TGGCAGATGAAATATGGCTAGGT-3
  reverse 5-GAGAGTTCTGACTGGGAGATCTC-3
- TRPC4: forward 5-TCAGAGGTCTCTGATGCTCTTTGATCTC-3
  reverse 5-TCTGAGATGCTGAGATCTC-3
- TRPC5: forward 5-TGAGGGCCGTCCAAGGTCG-3
  reverse 5-GAGGGCCGTCCAAGGTCG-3
- TRPC6: forward 5-TCTCCCATGATGTGACTCCAAA-3
  reverse 5-GAGGGCCGTCCAAGGTCG-3
- TRPC7: forward 5-GGGTAATGACGACG-3
  reverse 5-TCAGGATGCTGAGATCTC-3
- TRPC8: forward 5-GGGAACGAGGACTCTAGG-3
  reverse 5-GGGAACGAGGACTCTAGG-3
- TRPC9: forward 5-GCAGGCTGACGAGGACTCTAGG-3
  reverse 5-GGGAACGAGGACTCTAGG-3
- TRPC10: forward 5-GACGAGGACTCTAGG-3
  reverse 5-GGGAACGAGGACTCTAGG-3
- TRPC11: forward 5-GGGAACGAGGACTCTAGG-3
  reverse 5-GGGAACGAGGACTCTAGG-3

Statistical Data Analysis
Statistical significances between treatments and controls were analyzed with Student’s t test using GraphPad Prism 3.0. Differences in the comparison tests lower than P < 0.01 were considered significant.

Results

1. In vitro TRPV6 knockdown
The effect of TRPV6 knockdown on TRPV6 mRNA expression in T47D breast cancer cells was determined via real-time PCR (Fig. 1A). The TRPV6 mRNA level was significantly reduced in T47D cells after 72 h by two different TRPV6-specific siRNA molecules. The most effective siRNA molecule was siRNA2, which reduced the TRPV6 message by 47%. The siRNA1 had nearly the same effect on TRPV6 expression, subsequently reducing
the mRNA by 40%. The control siRNA did not significantly change TRPV6 expression and was comparable with untreated controls.

After the treatment of T47D cells for 72 h in 96-well plates with both siRNAs, the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt viability assay was done. Figure 1B shows the percentage of growth reduction, measured as viable cells, of siRNA-treated cells compared with siRNA control or vehicle-only control. All treatments were done in the presence of serum. C, apoptosis assay after treatment of T47D breast cancer cells with siRNAs (5 nmol/L) for 72 h. Apoptosis was measured by caspase-3/caspase-7 assay. *, P < 0.01 significant difference between untreated cells and control siRNA; **, P < 0.01 significant difference between control siRNA and TRPV6 siRNAs (two-tailed t test). D, calcium uptake activity measured by fluorescence-based FLIPR calcium 3 assay after 72 h of TRPV6 knockdown with siRNAs (5 nmol/L). Calcium uptake activity is shown in fluorescent units per second as the slope of the uptake rates. *, P < 0.01 significant difference between control siRNA and TRPV6 siRNAs (two-tailed t test). Columns, mean; bars, SD (n = 3).

The treatment of T47D cells with siRNA did not induce a large amount of apoptosis, as indicated by caspase-3/caspase-7 assay (Fig. 1C). Knocking down TRPV6 expression slightly increased the amount of apoptotic cells by 7% compared with control siRNA. Both siRNAs had similar effects on apoptosis. The treatment of cells with control siRNA produced a minimal increase in apoptotic cells, 4% more than the untreated control.

The reduced calcium channel activity after TRPV6 knockdown shows that siRNA treatment affects the function of the channel and illustrates the importance of the channel in this cell line. The knockdown led to a decrease in calcium uptake activity to 47% for siRNA1 and 48% for siRNA2 compared with control. The uptake activity was measured in real-time and displayed in fluorescent units per second (Fig. 1D).
quantitate expression by real-time PCR. Twelve cDNA samples from breast cancer tissue and 11 samples from normal mammary tissue were included in the analysis. The majority of samples originated from invasive ductal carcinoma tissue \((n = 9)\), whereas sample 3 (invasive lobular carcinoma), sample 5 (invasive mixed tubular carcinoma), and sample 9 (adenoid cystic carcinoma) were the only exceptions. The TRPV6 expression from the 11 normal mammary tissues was averaged and used to compare expression from individual carcinoma tissue samples. Thus, the data in Fig. 2 is represented as fold difference over normal. From this analysis, TRPV6 mRNA expression in 7 of 12 patients was detected to be up-regulated between 2-fold and 15-fold over the average in normal breast tissue (Fig. 2). In eight samples, TRPV6 transcript levels were up-regulated on average at 4.6-fold compared with the normal tissue average. Furthermore, the coefficient of variance of TRPV6 expression in normal breast tissue was 8% \((n = 11)\). TRPV6 expression in the breast cancer samples was over twice as variable as in normal tissue, showing a coefficient of variance of 17% \((n = 12)\).

**In vitro Hormone Effects on TRPV6 Expression**

The most common treatments for breast tumors are hormonal treatments that act on the estrogen receptor to control breast cancer cell growth. Therefore, we investigated whether estrogen and progesterone could regulate the expression of TRPV6. The influence of these two hormones and controls on TRPV6 mRNA expression was determined via real-time PCR. T47D cells were treated with different concentrations of estradiol, progesterone, and 1α,25-dihydroxyvitamin D3. Additionally, tamoxifen, an estradiol receptor antagonist which is used in breast cancer therapy, and 5-fluorouracil, a compound used in several cancer therapies, were assessed for their affects on TRPV6 transcription regulation.

Dose and time experiments were done to determine adequate concentration and treatment times. Figure 3 shows the TRPV6 mRNA expression compared with vehicle-treated controls after 24-h, 48-h, and 72-h treatments with estradiol (10 nmol/L), progesterone (100 nmol/L), a combination of both estradiol and progesterone, 1α,25-dihydroxyvitamin D (100 nmol/L), tamoxifen (1 μmol/L), and 5-fluorouracil (1 μmol/L). After 24 h, the effect of progesterone on TRPV6 expression was only slightly different compared with vehicle-treated control. A time-dependent increase in expression was seen with estradiol after 24 h, wherein, after 72 h, the TRPV6 mRNA increased 69%. Treatment with progesterone also had a mild effect on increasing TRPV6 expression up to 56% after 72 h. Both hormones applied together stimulated induction of TRPV6 levels 96% over control when cells were treated for 72 h.

The estrogen receptor antagonist tamoxifen inversely affected TRPV6 expression at all time points tested. Tamoxifen moderately reduced the TRPV6 mRNA by 31% at 24 h and was slightly less effective after 48 and 72 h when used at 1 μmol/L. A log dose-response study was done with 24 h of treatment time from which it was evident that reducing the tamoxifen concentration lessens the effect on TRPV6 mRNA (Fig. 4A). Dosing the cells with 10 μmol/L tamoxifen reduced TRPV6 mRNA by 35%. The highest dose tried with tamoxifen was 50 μmol/L; however, the cells became apoptotic. At 100 nmol/L, tamoxifen only slightly reduced (12%) the TRPV6 expression level.

The hormone 1α,25-dihydroxyvitamin D (100 nmol/L) was on its own far more potent at stimulating TRPV6 mRNA expression (114%) when the T47D cells were treated for 24 h (Fig. 4B). However, the stimulatory effect seen reduced over time and lead to only 39% induction after a 72-h treatment. A dose-dependent relationship can be seen during a 24-h treatment as seen in Fig. 4B. With log reductions of 1α,25-dihydroxyvitamin D concentration, the stimulation effect nearly disappears at 100 pmol/L (14%).

As a control, 5-fluorouracil was used as another anticancer compound with an estrogen receptor–independent mechanism (Fig. 3). After 24 h with 5-fluorouracil (1 μmol/L), the treatment had no effect on TRPV6 mRNA level. There was a slight up-regulation, 14% and 21%, after 48 and 72 h.

![Figure 2](Image)

**Figure 2.** TRPV6 mRNA expression in 12 breast cancer tissue samples compared with the average of 11 normal samples based on real-time PCR. TRPV6 was measured by real-time PCR and standardized via h-actin. The data is represented as fold difference compared with the average expression from 11 normal breast tissue samples. Columns, mean; bars, SD \((n = 6)\).
Tamoxifen Effect on TRPV6 Calcium Transport Activity

TRPV6-expressing oocytes were used to probe the inhibition effect of tamoxifen on calcium transport. The drug showed a dose-responsive blocking ability on TRPV6 mediated $^{45}$Ca$^{2+}$ uptake into oocytes (Fig. 5). Tamoxifen inhibits the channel with an IC$_{50}$ value of 7.5 μmol/L, which suggests that it may have an additionally beneficial mechanism to slow the growth of breast cancer cells. The IC$_{50}$ value was determined using nonlinear data fitting (GraphPad Prism version 3.0).

Calcium Channel Expression in T47D Cells

To investigate the mRNA predominance of TRPV6 in T47D breast cancer cells, the expression of it and expression of other calcium channels in this cell line were determined with reverse transcription–PCR and gel electrophoresis. Figure 6 shows the relative expression levels of the calcium channels: TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPV5, and TRPV6 in T47D cells. From this analysis, TRPC4, TRPC6, and TRPV6 are the most predominately expressed calcium channels on the RNA level.

Discussion

The TRPV6 calcium entry channel has previously been shown to be linked to prostate tumor progression and inhibits the channel with an IC$_{50}$ value of 7.5 μmol/L, which suggests that it may have an additionally beneficial mechanism to slow the growth of breast cancer cells. The IC$_{50}$ value was determined using nonlinear data fitting (GraphPad Prism version 3.0).
Amplicons range in size from 100 to 150 bp.

Figure 6. Relative RNA expression levels of calcium channels as determined by semiquantitative reverse transcription–PCR. MW (lane 1), TRPC1A (lane 2), TRPC3 (lane 3), TRPC4 (lane 4), TRPC5 (lane 5), TRPC6 (lane 6), TRPC7 (lane 7), TRPV6 (lane 8), and TRPV5 (lane 9) in T47D cells. Amplicons range in size from 100 to 150 bp.

development. The role of TRPV6 in the progression of tumor cells is not completely clear but seems to involve accumulation of cellular calcium to promote cancer cell growth or survival.

Previously, it has been shown that TRPV6 seemed to be up-regulated on the protein level in breast adenocarcinoma tissue (8). In this report, we further investigated the expression level of TRPV6 in breast cancer tissue from patients compared with normal mammary tissue. In the 12-patient samples analyzed by real-time PCR, eight samples had TRPV6 transcript levels that were up-regulated on average of 4.6-fold compared with the normal tissue average. This further strengthens our earlier observation where we see up-regulation on the protein level (8). There are associated estrogen receptor and progesterone receptor values for each cancer tissue sample (data not shown), but we were unable to find any clear, statistically significant correlation between these values and TRPV6 expression.

We investigated this relationship under more controlled conditions to see how estrogen receptor may regulate TRPV6 in breast cancer cells in vitro. When stimulated with estrogen for 24 h, the RNA transcript of TRPV6 was slightly reduced compared with vehicle only–treated cells. Likewise, when prostate cancer cells were treated with dihydrotestosterone for a similar period of time, the transcription of TRPV6 also decreased (7). In contrast, when activated longer with estrogen from 48 to 72 h, the cells increased the transcription of TRPV6 up to 69%. It has long been known that estrogen promotes T47D cell proliferation (23, 24). Long-term up-regulation of TRPV6 seems to be part of this cell growth mechanism. The antiestrogen tamoxifen showed interesting activity upon TRPV6 expression at all time points tested. Blocking the estrogen receptor with tamoxifen caused the TRPV6 transcript levels to reduce. The limited signaling that can occur from estrogen receptor seems to lead to lower TRPV6 expression. And with increasing concentrations of tamoxifen, this effect becomes even more pronounced. These observations suggest that the estrogen receptor is able to regulate TRPV6 expression to possibly promote increased calcium entry into the cells. When used at low concentrations (0.1–1 μmol/L), tamoxifen has been shown to induce G1 cell cycle arrest in T47D cells, thereby stopping cell proliferation (23, 25). Correspondingly, the T47D cells reduced TRPV6 expression, which acts negatively to inhibit cell growth. Larger doses of tamoxifen (>5 μmol/L) have been reported to induce apoptosis in T47D cells (26). In our studies, we have observed that the activity of tamoxifen was enhanced by knocking down TRPV6 expression. We would expect a stronger enhancement if the expression was further knocked down. However, affecting the channel activity may be done more effectively through designing TRPV6-specific chemical inhibitors. These studies show that a combination therapy using tamoxifen and a TRPV6 inhibitor would be a beneficial approach to treating breast cancer cells.

Estrogen is known to induce increased calcium absorption via up-regulating TRPV6 in female mouse intestine via a vitamin D–independent mechanism (6). During pregnancy, the increased calcium absorption is needed to compensate for increased nutritional demands. Likewise, 1,25-vitamin D is also a known TRPV6 stimulator, as shown in this study and previous studies (27). At low concentrations (0.05–0.8 nmol/L), vitamin D promotes growth (28), whereas increasingly higher concentrations cause cell cycle block in G1 phase and subsequent apoptosis (29, 30). In our experiments, we see that TRPV6 expression reduces significantly, after 24 h after 1,25-vitamin D (100 nmol/L) treatment. Thus, this effect seems to be in coordination with the T47D cell reducing its proliferation.

Additionally, we observed that tamoxifen cannot only down-regulate TRPV6 mRNA expression, but it can directly inhibit the calcium channel activity. We observed this effect when we expressed TRPV6 in Xenopus oocytes, giving an IC50 value of nearly 7.5 μmol/L. This is intriguing, given the fact that it is an estrogen receptor inhibitor. However, it does share several structural similarities with known T-type calcium channel inhibitors, such as a tertiary nitrogen, aromatic groups, and an ether bond. In support of this, it can be found in the literature that both tamoxifen and raloxifene are able to affect calcium channel activity. In whole-cell patch clamp studies in vascular smooth muscle cells, tamoxifen reduced the current through L-type calcium channels with an ID50 of 2 μmol/L and through T-type channels with 10 μmol/L (31). The antiestrogen SERM, raloxifene, is also known to affect voltage sensitive L-type calcium channel activity (32–34).

Tamoxifen is also known to be effective in ~10% estrogen receptor–negative and progesterone receptor–negative patients (19, 20). This might suggest that tamoxifen is directly acting on the TRPV6 calcium channel in those patients. Therapeutic concentration of tamoxifen in the breast cancer tissue can reach low micromolar values (35). Therefore, IC50 concentration for TRPV6 inhibition measured in oocytes is in a similar range to what has been seen in tumor tissues and, thus, may be clinically relevant in the affect of the drug. Regardless, it would be interesting to collect data on TRPV6 expression along with receptor values when assessing the effectiveness of tamoxifen in patients. More specific TRPV6 inhibitors could be used to regulate the growth of breast tumor cells expressing TRPV6.

In the T47D breast cancer cells, TRPV6 is one of several potential calcium entry channels expressed, but TRPV6
is the only calcium-specific entry channel present. The importance of TRPV6 could be seen after siRNA knockdown studies, because the proliferation rate of the cancer cells was reduced by 60% and calcium transport was reduced by 50%. Importantly, the siRNA knockdown of TRPV6 was not complete in these experiments so the full influence in these cells could not be fully assessed. There are two other potential calcium permeable channels, TRPC4 and TRPC6, which could also be contributing to the calcium uptake into these cells. However, these channels are receptor-operated, nonselective cation channels (36). Specifically, TRPC6 behaves as a nonselective cation channel that is activated by diacylglycerol in a membrane-delimited fashion, independently of protein kinase C (37). The TRPC6 channel is not considered to be store-operated and only has limited Ca\(^{2+}\) permeability relative to monovalent cation permeability (38). We cannot rule out their contributions at this time, but our results indicate that TRPV6 has a major influence on cellular calcium entry.

The breast cancer cells used in this study were slowed by reduced calcium channel expression and lower calcium uptake potential. The stable expression of TRPV6 in the kidney cell line HEK-293 promoted increased cellular proliferation and calcium accumulation (15). Clearly, the calcium state inside cells can influence their proliferation rate. Furthermore, previous studies in prostate cancer cell lines indicate that TRPV6 plays a significant role in prostate cancer calcium influx (39,40).

In T47D cancer cells, TRPV6 also contributes a rather significant portion of the calcium entry activity and leads to a large reduction (~60%) in the proliferative ability of the cells. Furthermore, it was found that treatment with TRPV6-specific siRNAs produced a small increase (~7%) in apoptosis in the breast cancer cells, as indicated by a caspase-3/caspase-7 assay. Therefore, the net result indicates that the cancer cells are growing less rapidly than dying from reduced calcium uptake. Silencing TRPV6 in the breast cancer cells may be causing cell cycle arrest, which may explain the less rapid cell proliferation. We have not provided direct evidence for this, but it has been shown that TRPV6 silencing in the prostate cancer cell line LNCaP results in a reduced number of cells entering S phase (39). Similar to our study, the LNCaP cells show a higher rate (~15%) of apoptosis after specific TRPV6 siRNA knockdown (39). From their study in LNCaP, it was suggested that calcium entry via TRPV6 not only maintains an increased proliferation rate but increases cellular survival and provides resistance to apoptosis. Here, we see similar results; however, in T47D cells, TRPV6 seems to provide less resistance to apoptosis. This may be due to the presence of TRPC4, TRPC6, or other entry channels permeable to calcium or insufficient TRPV6 knockdown. Therapeutic treatments aimed at inhibiting the TRPV6 channel would thus keep the cancer cells from rapidly growing. For instance, it has been shown that calcium channel inhibitors that likely block TRPV6 are able to restrict the growth of prostate cancer cells in a cytostatic manner and, when given to mice, show no toxicity (41).

In this study, we have shown that TRPV6 is expressed at elevated messenger levels in breast cancer patient samples. In our in vitro model, estrogen, progesterone, and 1,25-vitamin D were all able to regulate TRPV6 transcription. Interestingly, tamoxifen acts negatively on two levels to reduce both the expression and activity of TRPV6. This suggests that TRPV6 might be involved in the antiproliferative activity of the widely used breast cancer treatment tamoxifen. However, further clinical data would be needed to address this hypothesis. Regardless, TRPV6 seems to be able to control the proliferative ability of T47D breast adenocarcinoma cells. The activity of tamoxifen was enhanced by combination treatment with TRPV6 silencing siRNA. Our studies indicate that TRPV6 may be suitable target for development of specific chemical inhibitors. Furthermore, when hormonal therapies are no longer effective, inhibitors for TRPV6 may be of increased value, particularly when the tumors become estrogen receptor–negative or progesterone receptor–negative.

References

Mol Cancer Ther 2008;7(2). February 2008


Article on TRPV6 in Breast Cancer

In the article on TRPV6 in breast cancer in the February 2008 (1) issue, the text in the legend to Fig. 4A and B on page 276 was incorrect. The correct Fig. 4 and legend appear below.

Reference

Figure 4. A, dose-dependent effect of tamoxifen (1nM, 10nM, 100nM, 1uM, and 10uM) on TRPV6 mRNA expression in T47D cells after 24 h determined via real-time PCR. B, dose-dependent effect of 1α,25 dihydroxyvitamin D (100 pM, 1nM, 10nM, and 100nM) on TRPV6 mRNA expression in T47D cells after 24 h determined via real-time PCR. Data shown are percent change in TRPV6 mRNA compared with vehicle only control. Columns, mean; bars, SD (n = 3).
Molecular Cancer Therapeutics

The role of TRPV6 in breast carcinogenesis
Katrin A. Bolanz, Matthias A. Hediger and Christopher P. Landowski

Mol Cancer Ther 2008;7:271-279. Published OnlineFirst February 1, 2008.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-07-0478

Cited articles
This article cites 41 articles, 13 of which you can access for free at:
http://mct.aacrjournals.org/content/7/2/271.full.html#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
/content/7/2/271.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.